Shanghai Junshi Biosciences Co (HKSE:01877) Total Inventories : HK$581.8 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co Total Inventories?

Shanghai Junshi Biosciences Co's total inventories for the quarter that ended in Mar. 2024 was HK$581.8 Mil. Shanghai Junshi Biosciences Co's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was HK$585.1 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Shanghai Junshi Biosciences Co's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was HK$0.04.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Shanghai Junshi Biosciences Co's Days Inventory for the three months ended in Mar. 2024 was 454.71.

Inventory Turnover measures how fast the company turns over its inventory within a year. Shanghai Junshi Biosciences Co's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.20.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Shanghai Junshi Biosciences Co's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 1.41.

Shanghai Junshi Biosciences Co Total Inventories Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Total Inventories Chart

Shanghai Junshi Biosciences Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

201.04

407.11

593.38

668.94

588.51

Shanghai Junshi Biosciences Co Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial														-	713.73	-	588.51	581.77

Shanghai Junshi Biosciences Co Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Shanghai Junshi Biosciences Co (HKSE:01877) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Shanghai Junshi Biosciences Co's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(4952.785	+	0.75 * 534.547	+	0.5 * 581.767	-	5437.669
-	0	-	165.951)	/	985.69
=	0.04

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Shanghai Junshi Biosciences Co's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	585.139	/	117.423	*	365 / 4
	=	454.71

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Shanghai Junshi Biosciences Co's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	117.423	/	585.139
	=	0.20

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Shanghai Junshi Biosciences Co's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	585.139	/	413.668
	=	1.41

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Shanghai Junshi Biosciences Co Total Inventories Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

8SJ:Germany 688180:China

Address

Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN

Website

https://www.junshipharma.com

Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Executives

Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Highbury Investment Pte Ltd	2101 Beneficial owner
Jovial Champion Investments Limited	2201 Interest of corporation controlled by you
Gong Ruilin	2202 Interest of your spouse
Vistra Trust (singapore) Pte. Limited	2201 Interest of corporation controlled by you
Lvc Holdings Limited	2201 Interest of corporation controlled by you
Lvc Management Holdings Limited	2201 Interest of corporation controlled by you
Lvc Innovate Limited	2201 Interest of corporation controlled by you
Lin Lijun	2307 Founder of a discretionary trust who can infl
Lvc Renaissance Fund Lp	2101 Beneficial owner
Lvc Renaissance Limited	2201 Interest of corporation controlled by you
Loyal Valley Innovation Capital (hk) Limited	2201 Interest of corporation controlled by you
Lv Di Kong Gu Ji Tuan Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines